Article Sidebar

pdf
Date Published: 11/03/2026
Abstract Views: 24
Views pdf: 12
DOI: https://doi.org/10.51298/vmj.v559i3.17664
Issue
Vol. 559 No. 3 (2026)
Section
Các bài báo
How to Cite
Chung, T. N., Võ , H. M. C., & Ngô, T. T. D. (2026). ASSOCIATION BETWEEN METABOLIC ASSOCIATED FATTY LIVER DISEASE AND ATHEROSCLEROTIC LOWER EXTREMITY ARTERIAL DISEASE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS. Vietnam Medical Journal, 559(3). https://doi.org/10.51298/vmj.v559i3.17664

ASSOCIATION BETWEEN METABOLIC ASSOCIATED FATTY LIVER DISEASE AND ATHEROSCLEROTIC LOWER EXTREMITY ARTERIAL DISEASE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS

Thiện Nhân Chung, Hồng Minh Công Võ , Thị Thùy Dung Ngô

Main Article Content

Abstract

Objective: To determine the association between metabolic associated fatty liver disease (MAFLD) and atherosclerotic lower extremity arterial disease (LEAD) in patients with type 2 diabetes mellitus. Methods: A cross-sectional study was conducted on 212 type 2 diabetes mellitus patients at Gia Dinh People’s Hospital and Thong Nhat Hospital in 2024. Results: The prevalence of MAFLD in the study population was 71.2%. Atherosclerotic plaques in lower extremity arteries were more frequently observed in patients with MAFLD (p = 0.003); however, no significant difference was found in the prevalence of LEAD between groups (p >0.050). Multivariate logistic regression analysis showed that MAFLD increased the risk of developing atherosclerotic plaques in the lower extremity arteries in T2DM patients, with an odds ratio (OR) of 2.83 (95% CI: 1.45 – 5.53, p = 0.002). Conclusion: MAFLD is associated with the presence of atherosclerotic plaques in the lower extremity arteries but not with LEAD in patients with type 2 diabetes mellitus.

Article Details

Keywords

Metabolic associated fatty liver disease, lower extremity arterial disease, type 2 diabetes mellitus.

References

1. Đỗ Minh Quân, Trần Thị Khánh Tường, Cao Đình Hưng, cs. Tỷ lệ bệnh gan nhiễm mỡ liên quan rối loạn chuyển hóa ở bệnh nhân đái tháo đường típ 2. Tạp chí Y học Việt Nam. 2024;534(1B):319-322.
2. Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41(2):255–323.
3. Guo K, Zhang L, Lu J, et al. Non-alcoholic fatty liver disease is associated with late but not early atherosclerotic lesions in Chinese inpatients with type 2 diabetes. J Diabetes Complications. 2017;31(1):80–5.
4. Karlas T, Petroff D, Garnov N, et al. Non-invasive assessment of hepatic steatosis in patients with NAFLD using controlled attenuation parameter and 1H-MR spectroscopy. PLoS One. 2014;9(3):e91987.
5. Méndez-Sánchez N, Díaz-Orozco LE. Editorial: International Consensus Recommendations to Replace the Terminology of Non-Alcoholic Fatty Liver Disease (NAFLD) with Metabolic-Associated Fatty Liver Disease (MAFLD). Med Sci Monit. 2021;27:e933860.
6. Schaberle W. Ultrasonography in Vascular Diagnosis – A Therapy-Oriented Textbook and Atlas. Springer; 2018.
7. Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med. 2010;363(14):1341–50.
8. Tuong TTK, Tran DK, Phu PQT, et al. Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes: Evaluation of Hepatic Fibrosis and Steatosis Using FibroScan. Diagnostics (Basel). 2020;10(3):1–11.
9. Wong VW, Vergniol J, Wong GL, et al. Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. Hepatology. 2010;51(2):454–62.
10. Zou Y, Li X, Wang C, et al. Association between non-alcoholic fatty liver disease and peripheral artery disease in patients with type 2 diabetes. Intern Med J. 2017;47(10):1147–53.